Compare Ovintiv Inc. (DE) (OVV) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ovintiv Inc. (DE) vs Repligen Corporation Common Stock — how do they compare? Ovintiv Inc. (DE) trades at $66.75 (market cap $18.46B), while Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B). The key difference: Ovintiv Inc. (DE) is the larger of the two by market cap, and Ovintiv Inc. (DE) pays a 1.8% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ovintiv Inc. (DE) for 6 Days and Repligen Corporation Common Stock for 0 Days on average.
| OVV | RGEN | |
|---|---|---|
Market Cap | $18.46B | $11.31B |
Volume | 3,605,589 | 1,216,919 |
Sector | Energy | Health |
52-Week High | $66.97 | $194.57 |
52-Week Low | $35.97 | $102.87 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $22.79B | $11.20B |
Dividend Yield | 1.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OVV trades at $66.66, up 2.36% today, with a bullish technical outlook supported by moving averages and strong analyst consensus. The company reported mixed Q2 2026 earnings, missing EPS estimates but showing robust revenue growth. Recent news highlights expansion in Permian and Montney assets, share buybacks, and strong free cash flow generation, positioning the stock for potential upside.
The outlook for OVV is positive, driven by operational strength and strategic acquisitions, though risks include commodity price volatility and natural gas headwinds. With a consensus price target of $76.00 and no sell ratings, Wall Street sentiment remains bullish, offering a favorable risk-reward profile for investors seeking energy exposure.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ovintiv Inc. (DE)
Ovintiv explores for and produces oil and natural gas in North America. Its operations are concentrated in major U.S. and Canadian resource basins.
Read more on OVV →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
